Successful implementation of rituximab in patients with severe refractory forms of granulomatosis with polyangiitis
Abstract
Abstract
Introduction. Wegeners’s granulomatosis is a disease characterized by granulomatous inflammation of the upper and/or lower respiratory tract, glomerulonephritis with varying degrees of small vessel vasculitis and classic anti-neutrophil cytoplasmic antibodies (c-ANCA) findings. The treatment uses different modalities of immunosuppressive therapy which does not always lead to remission. We presented the efficacy of biological therapy in a patient with refractory form of the Wegeners’s granulomatosis. Case report. A 23-years-old patient, was treated in August, 2011 at the Clinic of Otorhinolaryngology and Maxillofacial Surgery of the Clinical Center of Serbia because of suppurative otitis media, resulting twice in mastoidectomy. On the day 7 after the surgery, hemoptysis and fever occurred. Considering lung x-ray that showed presence of the round soft-tissue changes on both sides, nonspecific inflammatory syndrome in laboratory analysis and positive c-ANCA (1 : 160) with high titers the antibodies to the proteinase 3 (anti-PR 3), Wegener's granulomatosis was diagnosed. Due to the fact that administration of glucocorticoids, cyclophosphamide and immunomodulatory dose of immunoglobulin did not lead to clinical remission, it was decided to apply rituximab. After its application clinical remission occurred and it lasted fifteen months. Conclusion. Application of biologic therapy might be successful in the treatment of patients with severe form of refractory granulomatosis with polyangiitis.
References
REFERENCES
Ebrahim AK, Loock JW. Case of acute, resistant fulminant We-gener's granulomatosis successfully treated by rituxi¬mab. J La-ryngol Otol 2013; 127(4): 411‒4.
Lutalo PM, D'Cruz DP. Diagnosis and classification of granu-lomatosis with polyangiitis (aka Wegener's granulo¬matosis). J Autoimmun 2014; 48‒49: 94‒8.
Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, et al. Predictors of relapse and treatment resistance in anti-neutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005; 143(9): 621‒31.
Adler S, Villiger PM. B cell strategy to maintain remission in ANCA-associated vasculitides? J Rheumatol 2012; 39(1): 4‒5.
Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L,et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18(7): 2180‒8.
Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, et al. Azathioprine or methotrexate mainte¬nance for AN-CA-associated vasculitis. N Engl J Med 2008; 359(26): 2790‒803.
Bosch X, Guilabert A, Espinosa G, Mirapeix E. Treatment of an-tineutrophil cytoplasmic antibody associated vasculitis: a sys-tematic review. JAMA 2007; 298(6): 655‒69.
Specks U. Biologic agents in the treatment of granulomato¬sis with polyangiitis. Cleve Clin J Med 2012; 79 Suppl 3: S50‒3.
Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroe¬der DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173(2): 180‒7.
Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363(3): 221‒32.
De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al. Randomized trial of cyclophos¬phamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associ¬ated vasculitis. Arthritis Rheum 2005; 52(8): 2461‒9.
Pescovitz MD. Rituximab, an anti-cd20 monoclonal anti¬body: history and mechanism of action. Am J Transplant 2006; 6(5 Pt 1): 859‒66.
Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363(3): 211‒20.
Cartin-Ceba R, Golbin JM, Keogh KA, Peikert T, Sánchez-Menéndez M, Ytterberg SR, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a sin¬gle center. Arthritis Rheum 2012; 64(11): 3770‒8.
Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013; 369(5): 417‒27.